OCUFLOX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OCUFLOX (OCUFLOX).
Inhibits bacterial DNA gyrase and topoisomerase IV, thereby interfering with bacterial DNA replication, transcription, repair, and recombination.
| Metabolism | Systemic fluoroquinolones are primarily metabolized via hepatic glucuronidation and CYP450 isoenzymes; however, ophthalmic administration results in minimal systemic absorption, so hepatic metabolism is not clinically significant. |
| Excretion | Ofloxacin is primarily excreted unchanged in the urine via glomerular filtration and tubular secretion, accounting for 70-80% of an administered dose. Approximately 4-8% is excreted in feces via biliary secretion. Renal excretion is the major route. |
| Half-life | Terminal elimination half-life is approximately 5-7 hours in patients with normal renal function. This may be prolonged to 21-56 hours in severe renal impairment (CrCl <20 mL/min), necessitating dosing adjustments. |
| Protein binding | Approximately 20% bound to serum proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 1.5-2.5 L/kg (range 1.2-2.9 L/kg), indicating extensive tissue penetration, including into ocular tissues, respiratory tract, and urogenital system. |
| Bioavailability | Ophthalmic administration results in negligible systemic bioavailability (<5% of dose absorbed). Oral bioavailability is approximately 98%, with peak serum concentrations achieved 1-2 hours after oral dosing. |
| Onset of Action | Following ophthalmic administration, clinical effect (e.g., bacterial conjunctivitis symptom relief) typically begins within 24-48 hours, with significant improvement by 48-72 hours. |
| Duration of Action | For ophthalmic use, duration of antimicrobial effect is approximately 6-8 hours per dose, supporting QID (four times daily) dosing. Ofloxacin levels in tears remain above MIC90 for common ocular pathogens for up to 6 hours. |
| Molecular Weight | 361.37 |
1-2 drops into the affected eye(s) every 2-4 hours for the first 2 days, then 1-2 drops 4 times daily for an additional 5 days.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dosage adjustment required for renal impairment as systemic absorption is minimal. |
| Liver impairment | No dosage adjustment required for hepatic impairment as systemic absorption is minimal. |
| Pediatric use | 1-2 drops into the affected eye(s) every 2-4 hours for the first 2 days, then 1-2 drops 4 times daily for an additional 5 days. Safety and efficacy in children <1 year have not been established. |
| Geriatric use | No specific dosage adjustment required; use same dosing as adults. |
| 1st trimester | Ofloxacin, a fluoroquinolone, is generally avoided during pregnancy due to concerns from animal studies showing arthropathy in immature animals. Human data are limited; however, fluoroquinolones are not recommended during the first trimester unless the benefit outweighs the risk, as there is a potential for fetal harm. |
| 2nd trimester | Limited human data; animal studies have not shown teratogenicity but have demonstrated fetal toxicity at high doses. Use only if clearly needed and no safer alternative exists. |
| 3rd trimester | Avoid use during third trimester due to potential risk of fetal cartilage damage and arthropathy, as seen in immature animals. Alternative antibiotics are preferred. |
Clinical note
Comprehensive clinical and safety monograph for OCUFLOX (OCUFLOX).
| Placental transfer | Ofloxacin crosses the placenta. In a study, cord blood concentrations were about 60% of maternal plasma levels, indicating moderate transfer. |
| Breastfeeding |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to ofloxacin or any fluoroquinoloneHistory of tendinopathy or tendon rupture with fluoroquinolonesPregnancy (especially third trimester) - relative contraindication; absolute if safer alternatives existChildren <18 years of age (except for specific infections like cystic fibrosis) due to risk of arthropathy
| Precautions | Prolonged use may result in overgrowth of nonsusceptible organisms including fungi., Hypersensitivity reactions: rare but can be serious, including anaphylaxis, Stevens-Johnson syndrome., Patients should not wear contact lenses during treatment of bacterial conjunctivitis., Ophthalmic solutions may cause transient stinging or burning upon instillation. |
| Food/Dietary | No significant food interactions with ophthalmic ofloxacin due to minimal systemic absorption. However, avoid rubbing eyes after application if hands have food residue to prevent irritation. |
Loading safety data…
| Ofloxacin is excreted into breast milk in small amounts (approximately 0.1-0.2% of maternal dose). The American Academy of Pediatrics considers fluoroquinolones compatible with breastfeeding due to low transfer. However, caution is advised in neonates or premature infants due to potential joint toxicity. Monitor infant for diarrhea or thrush. |
| Lactation Rating | L2 |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. Animal studies show no evidence of teratogenicity at doses up to 810 mg/kg/day (approximately 750 times the human ophthalmic dose). Risk cannot be ruled out; use only if potential benefit justifies potential risk. |
| Fetal Monitoring | No specific monitoring required beyond usual prenatal care. Monitor for adverse effects in infant if used near term. |
| Fertility Effects | No known effects on fertility. Animal studies at high oral doses showed no impairment. |
| Clinical Pearls | OCUFLOX (ofloxacin ophthalmic solution) is a fluoroquinolone antibiotic used for ocular infections. Do not use to treat viral or fungal eye infections. Frequent administration ensures high tear film concentrations. Avoid prolonged use to prevent resistance. Use with caution in patients with corneal epithelial defects as it may retard healing. Cross-allergenicity with other fluoroquinolones is possible. |
| Patient Advice | Shake the bottle well before each use. · Do not touch the dropper tip to the eye or any surface to avoid contamination. · Remove contact lenses before instillation and wait at least 15 minutes before reinserting. · Apply prescribed number of drops; if using more than one drop, wait 5 minutes between drops. · Do not use the solution if it changes color or becomes cloudy. · Complete the full course even if symptoms improve. · Report eye pain, redness, or vision changes immediately. · Store at room temperature away from light and moisture. |